Yeast Genomics Technique for High-Throughput Drug Target Discovery

Authors

  • Zijun Sun,

    1. The Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Southeast University, Nanjing, China
    Search for more papers by this author
  • Yanyan Sun,

    1. The Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Southeast University, Nanjing, China
    Search for more papers by this author
  • Yaxian Zhou,

    1. The Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Southeast University, Nanjing, China
    Search for more papers by this author
  • Yakun Wan

    Corresponding author
    • The Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Southeast University, Nanjing, China
    Search for more papers by this author

Correspondence to: Yakun Wan, The Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Southeast University, Nanjing 210096, China.

E-mail: ywansystemsbiology@gmail.com

Abstract

Preclinical Research

The budding yeast Saccharomyces cerevisiae has been a singularly useful eukaryote for the development of Chemical genomic techniques for use in drug discovery studies. Particularly, yeast genomic methodologies provide a solid foundation for high-throughput drug target identification. The success of genomic profiling in budding yeast led to the use of chemical genomics approaches in higher eukaryotic systems. In the present overview, the focus was principally on high-throughput chemical genomic technologies that are advancing the utility of yeast in the drug development research. This led to the review of chemical genomic technologies in other biological systems and the applications of drug synergy in pharmacological research. Finally, the development of genome-wide drug screening was reviewed in the context of drug synergy strategies for discovering novel combinatorial therapies.

Ancillary